DXCM Dexcom Earnings and EPS analysis
- Stocks
- Healthcare
- NASDAQ: DXCM
- Earnings
EPS in 2025 (TTM): $1.35
Last Report Period Date: Mar 31, 2025
Currently, DXCM's trailing twelve months (TTM) EPS stands at $1.35, according to the most recent financial reports. Dexcom's earnings per share in 2024 came in at $1.46, marking an increase from $1.4 in 2023. DXCM recorded an EPS of $0.27 for the quarterly period ending on Mar 31, 2025.
DXCM earnings history
In 2024, Dexcom's EPS was $1.46, an increase of 4.3% from $1.4 in 2023. The quarterly EPS for the period ending Mar 31, 2025, was $0.27, marking a 28.9% decline compared to the same quarter last year. DXCM's TTM EPS is $1.35 as of March 2025. Dexcom's EPS for 2023 was $1.4, a 59.1% rise from 2022.
DXCM EPS growth
Over the past 12 months, Dexcom has recorded an earnings per share growth of -28.9% (YoY, quarterly). Looking at a longer timeframe, the company recorded an average EPS annual growth rate of 37.6% per year for the last 3 years. Over the last five years, the company had an average annual EPS growth of 39.1%.
DXCM Earnings Waterfall
DXCM Earnings vs Peers
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| EW Edwards Lifesciences Corp | 11.1 | 202.2% | 42.5% | 33% |
| ABT Abbott Laboratories | 17.1 | 133.8% | 24.5% | 29.9% |
| JNJ Johnson & Johnson | 17.32 | -57.9% | -9.7% | 0.4% |
| MDT Medtronic plc | 24.77 | 31% | -1.1% | 0.3% |
| BDX Becton Dickinson & Co | 33.97 | 18.3% | -5.3% | 8% |
| WST West Pharmaceutical Services Inc | 35.39 | -15.4% | -8.8% | 15.6% |
| DXCM Dexcom Inc | 61.76 | 4.3% | 37.6% | 39.1% |
| TNDM Tandem Diabetes Care Inc | N/A | 57.1% | N/A | N/A |
| QDEL Quidel Corp | N/A | -20,260% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.